WO2011107295A1 - Kristalline formen zu 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung - Google Patents
Kristalline formen zu 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung Download PDFInfo
- Publication number
- WO2011107295A1 WO2011107295A1 PCT/EP2011/001124 EP2011001124W WO2011107295A1 WO 2011107295 A1 WO2011107295 A1 WO 2011107295A1 EP 2011001124 W EP2011001124 W EP 2011001124W WO 2011107295 A1 WO2011107295 A1 WO 2011107295A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- equivalents
- crystalline form
- vol
- crystalline
- ethanol
- Prior art date
Links
- HWYHZTIRURJOHG-UHFFFAOYSA-N Nc1cccc(C(NN2)=O)c1C2=O Chemical compound Nc1cccc(C(NN2)=O)c1C2=O HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to the provision of at least two new ones
- the invention relates to the provision of 2 new crystalline forms to 10 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt with immunostimulating and
- 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt also includes that of the present invention, which is known, for example, from EP 1 203 587 A and has the following basic structure (Na + not shown):
- the starting material is stable, non-hydrophobic and controllable in its solid behavior over the entire manufacturing process.
- chemical stability and solid phase stability with a long shelf life of an active ingredient is of outstanding importance (see Miller et al. (2006) in: Polymorphisms in the Pharmaceutical Industry, Hilfiker (Ed.) 385-403). It is desirable that even over a longer storage period, the physical
- Properties of the drug are preserved. This concerns e.g. the hygroscopicity, solubility or initial dissolution rate of the active ingredient.
- Residual products have allergenic potential and become one
- Process parameters cause changes in the crystal structure of the product and thus can result in other crystalline forms or mixed forms.
- altered properties for example, altered biological effectiveness due to a different solubility-can lead to the failure of entire batches, and sometimes it is no longer possible to produce the desired shape (see Ulrich and Jones (2005): panicen der Chemie 53: 19-23).
- the purity of the active ingredient and the resulting possible changes in the effectiveness of other important properties for pharmaceutical processing can be adversely affected, for example, the suitability for Tablettenverpressung by impairing the Flowability or flow rate of the crystalline form.
- 5-Amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts belong to the group of aminophthalhydrazides and are described in the prior art as immunomodulators with particular anti-inflammatory, anti-oxidative and anti-toxic properties (see US 6,489,326 B, EP 0617024, US 5,512,573, US 5,543,410 A, US 7,326,690 B2).
- Immunomodulatory substances are usually subdivided according to their effect into immunosuppressants and immune stimulants (see Rote Liste Service GmbH (201 1): www.rote-liste.de).
- immunosuppressants such as immunosuppressant TNF-alpha-blockers or immunostimulating interferon-beta preparations, often cause due to their very specific mechanism of action, significant undesirable side effects in the organism.
- Substances such as the TNF-alpha-blocker adalimumab, specifically inhibit certain inflammatory mediators.
- Such therapies are known to be associated with serious side effects (see Descotes (2008): Expert Opinion, Drug Metab. Toxicol., 4: 12: 1537-1549), because the blockade of individual inflammatory mediators represents a serious intervention in the complex immune system.
- the organism is no longer able to fulfill its function, i. independently and physiologically appropriate for exogenous or endogenous inflammatory stimuli, e.g.
- TNF-alpha-blockers are contraindicated in the case of serious infections, especially sepsis and tuberculosis.
- TBC screening is strongly recommended (see Diel et al. (2009): Z Rheumatol 5:41 1-416).
- Hoffmann was able to show clearly that TNF-alpha-blockers are not suitable for clinical use in septic states, but on the contrary can even lead to an increase in mortality.
- Immunosuppressants or preferably can be used as immune stimulants.
- 5-amino-2,3-dihydrophthalazine-l, 4-dione sodium salt describes the US2003 / 0195183 AI with the "correction of the immune system" by the use of different doses (0.2 micrograms up to 1,000 mg) of 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts in different experimental approaches: Effective doses within this range varied according to the investigated sample
- the property of a preferably stimulating immune modulator is desirable, for example, for the therapeutic treatment of patients who have weakened immune responses, such as as a result of HIV infection or as a result of chemotherapeutic treatment.
- a preferably suppressive immune modulator is desirable, for example to minimize inflammatory processes, such as in the context of surgery, in autoimmune diseases and allergies.
- a disadvantage of the prior art is further that a dose-dependent application of an immunomodulator requires increased attention of the applying medical staff or the patient himself and thus increases the risk of application errors.
- the present invention was made against the background of the prior art described above, and it was an object of the present invention to provide novel forms of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt having specific, distinct immunological effects , which can be used in such a targeted manner for predominantly immunosuppressive or predominantly immunostimulating purposes.
- these new forms are intended to show predominantly immune-stimulating or predominantly immunosuppressive effects regardless of dose.
- the forms provided should have physico-chemical properties which are intended to be produced singly or in combination, stored and / or used
- Crystalline form I and form II are defined by 10 characteristic values for interplanar distances and 2-theta angle values, expressed in one each
- forms I and II are positive physical Possess properties for pharmaceutical processing and application, including stability, storage stability, non-hygroscopicity and solubility. These are advantageous for the pharmaceutical production and further processing in comparison to, for example, dihydrates, in which there may be changes in the water content and, as a result, formulation problems, for example due to
- the inventors have also set themselves the task of providing methods which allow practicable and reproducible the novel anhydrate forms according to the invention to 5-amino-2,3-dihydrophthalazine-l, 4-dione sodium salt.
- the disclosed processes should do without the use of heavy metal catalysts and the production of the new crystalline form II reproducible for any batch sizes
- This object has been achieved by at least one process for the optional production of crystalline form I or II, in which sodium hydroxide and luminol are dissolved in water.
- a low molecular weight alcohol preferably ethanol or 2-propanol, precipitates crystalline luminol sodium salt.
- the desired crystalline form I or II is obtained after isolation and repeated washing and adherence to a specific stirring time.
- the inventive methods can be used for any batch quantities.
- the starting material for the preparation of both crystalline forms is as pure as possible Luminol or a method for producing the same by reduction of 3-nitrophthalic acid in an alkaline medium with a suitable reducing agent via 3-Nitrophthalanhydrid.
- Optional purification steps by recrystallization follow.
- the present invention comprises pharmaceutical formulations of the forms I or II or a combination thereof, each alone or together with pharmaceutically suitable excipients.
- Fig. 1 shows scanning electron images of Form I (top) and II (bottom).
- FIG. 2 describes a powder diffractogram of the crystalline form I.
- Fig. 3 describes a powder diffractogram of the crystalline form II.
- Fig. 4 describes the rate of dissolution of Forms I and II in water over time (20 minutes).
- Form I is represented by the lower of the two lines, Form II by the upper one.
- An “organism” is a living organism, especially human or animal, that is endowed with a self-regulating immunological system.
- active ingredient includes the crystalline form I or the crystalline form II or a mixture of both.
- pharmaceutical preparation includes the active ingredient in each
- pharmacologically appropriate, defined dosage and dosage form e.g. as a powder, suspension, emulsion and / or mixtures thereof. It includes pharmaceutically acceptable excipients, as well as all substances which arise directly or indirectly as a combination, accumulation, complex formation of the ingredients, or as a result of other
- Combination with other adjuvants and standard therapies may be formulated in accordance with the invention in liquid and solid form and administered in any medically acceptable manner, especially, but not limited to, intravenous, intramuscular, topical (e.g., eye drops), subcutaneous, transdermal, vaginal, rectally or orally, including sublingual and buccal, as well as in the form of substance-eluting implants.
- Liquid forms may be: eg solutions (eg for injections and infusions), suspensions, emulsions, sprays, lotions and ointments).
- Solid forms may be: tablets, dragees, capsules, powders or other forms which are familiar to the person skilled in the art and appear suitable, for example suppositories.
- adjuvant is used herein to refer to any component of a
- a suitable adjuvant depends on factors such as method of administration and dosage and on the influence of the solubility and stability of the preparation by the excipient itself.
- compositions for use in the desired form of application depending on the type of application may be, for example: sodium citrate, calcium phosphate,
- Calcium carbonate together with suitable disintegrating agents, e.g. for oral administration.
- suitable disintegrating agents e.g. for oral administration.
- suitable disintegrating agents e.g. for oral administration.
- suitable disintegrating agents which swell by water absorption (starch, cellulose derivatives, alginates, polysaccharides, dextrans, cross-linked polyvinylpyrrolidone), substances that develop by a chemical reaction with water gas (sodium bicarbonate, citric and tartaric acid) or substances which as hydrophilizing agents improve the wetting of the crystallites and thus mediate their dissolution in the water (eg polyethylene glycol sorbitan fatty acid esters).
- Adjuvants are also substances that can be used as binders, such as starch, gelatin, sugars, cellulose derivatives, or as thinners, such as sugar sweeteners.
- surface-active substances for example sodium lauryl sulfate or polysorbate 80, or lubricants, such as magnesium stearate, sodium stearate and further suitable to those skilled appear appropriate flavors, antioxidants, colorants and Preservatives.
- substantially pure means a purity of the active ingredient of at least 95%, preferably 98%, most preferably 99% 5-amino-2,3-dihydrophthalazine-1,4-dione
- immunospecific means the targeted use of Form I and / or Form II for the treatment of diseases with immunodeficient background or excessive immune system.
- effect describes the specific, here immunospecific, mode of action of an active substance in the context of this invention with predominantly immunostimulating or predominantly immunosuppressive action.
- the present invention includes a novel crystalline anhydrate Form I of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt characterized by
- the present invention further includes a novel crystalline anhydrate form II of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt characterized by
- Form II has, in particular, needle-like crystallites of octahedral structure of several micrometers in length, which are built up from layers, while in SEM of form I, morphologically non-uniform crystallites with rounded edges agglomerate in powder form (Fig. 1). From their crystal form arise for the forms of the invention advantageous properties for the
- Form II has a higher flowability and thus improved filterability compared to Form I, whereas Form I is better suited for tablet compression, in particular because of its higher bulk density, which is favored by its tendency to agglomerate, possibly due to the Gluing of its laminar substructures.
- Both crystalline forms are stable over a period of at least two months at room temperature (25 ° C) and 40 ° C and decompose only from 335 ° C ⁇ 10 ° C (Form I) and 385 ° C ⁇ 10 ° C (Form II), while in the dihydrate according to US Pat. No. 6,489,326 B1, an endothermic solid-phase transformation is already observed at 85 ° C. (Table 5).
- the decomposition temperatures of the forms I-II were determined with the same apparatus over 30-500 ° C in synthetic air (4 N 2 : 1 0 2 ). The data was with the factory
- thermoanalytical data confirms the inventors' assumption that both crystalline forms have advantageous properties in terms of stability and storage stability. These properties further favor the pharmaceutical processing of the inventive crystalline forms I and II over the dihydrate of the US
- both crystalline forms I and II are substantially stable with respect to a change in water content, so that formulation problems due to
- Table 6 Overview Solubility of Form I and Form II in water at room temperature in comparison with Dihydrate-US 6,489,326 B 1 preparable according to US 6,489,326 B 1
- Dissolution rate of Form II is higher in the first minutes after addition to an aqueous solution than Form I, which only reaches its full equilibrium concentration delayed.
- the different solubilities and initial rates of dissolution of Forms I and II may be due to their different surface structures ( Figure 1).
- the morphologically inconsistent rounded crystallites of Form I tend to have a more compact surface structure than the octahedral crystals of Form II, which, due to their shape, offer solvents a more accessible surface.
- the differences in the initial rate of dissolution between Forms I and II are particularly important for the preparation of oral formulations, since a slower rate of dissolution, as in Form I, offers advantages where sustained drug release is desired (sustained-release formulations).
- a faster rate of dissolution as in Form II is for the
- Formulation of oral acute medications advantageous in which the fastest possible and high bioavailability is sought.
- Luminolat molecules a sodium cation coordinates a total of 6 luminolate molecules in a trigonal prism via intermolecular hydrogen bonds
- in Form II there are only 4 luminolate molecules that are tetrahedral over intermolecular hydrogen bonds are arranged. This results in a thermally tends to be cheaper and more stable coordination of Form II over Form I.
- forms I and II can be used more specifically than the prior art because of their different immunomodulatory effect: While Form II exhibits an immunomodulating predominantly suppressive effect on certain cytokines, Form I exhibits a predominantly immunostimulating effect on certain cytokines. Form II is therefore particularly suitable for
- Form I is particularly suitable for therapeutic use in indications with excessive immune reactions
- the immune status of patients may change again and again so that a change from immunostimulating to immunosuppressive
- rheumatoid arthritis in particular active rheumatoid arthritis, relapsing multiple sclerosis, lupoid hepatitis, polyarteritis nodosa, Crohn's disease, ulcerative colitis, dermatomyositis, Behcet's disease, Behcet's disease uveitis, thrombocytopenic purpura, myasthenia gravis, Polymyositis, psoriasis, psoriatic arthritis, ankylosing spondylitis, paroxysmal nocturnal hemoglobinuria, ankylosing spondylitis, autoimmune thyroiditis, etc.), aplastic anemia, pemphigus, pemphigoid, endogenous uveitis, nephrotic syndrome and atopic dermatitis, and more preferably septic conditions induced by bacterial infections Gram-negative or Gram-positive pathogens, such as MRSA (Methicillin-
- conditions with immunodeficient background are, for example, frequent influenza infections, recurrent respiratory tract infections, recurrent infections of the urinary tract, fatigue, weakness, concentration disorders of unknown origin,
- Cytomegalovirus Epstein-Barr
- various oncological diseases in particular hairy cell leukemia, myeloid leukemia, multiple myeloma, follicular lymphomas, Kaposi's sarcoma, cutaneous T-cell lymphoma, nasopharyngeal carcinoma, carcinoid,
- Renal carcinoma urinary bladder carcinoma, basal cell carcinomas, metastatic carcinomas and more preferably malignant melanoma
- septic granulomatosis septic granulomatosis
- neutropenia neutropenia
- genital warts keratoses
- autoimmune diseases especially non-active stages such as relapsing multiple sclerosis
- radiogenic colitis diverticular disease
- allergies in particular Hay fever, polymorphic photodermatosis, eczema, neurodermatitis
- enteritis colitis, and particularly preferably concomitantly before, during and after chemotherapy and radiotherapy.
- Form II shows immunomodulatory properties which are advantageous affect activated macrophages.
- the inventors were able to prove predominantly immunosuppressive properties of Form II on the basis of in vitro experiments with LPS-stimulated macrophages. This resulted in a significant reduction in IL-6 levels.
- In vivo experiments on mice also showed a clear therapeutic efficacy of Form II.
- Macrophages are initially treated with Form I (20 or 200 g / mL). After 1 hour, the treated macrophages were stimulated with LPS (10, 100 or 1000 ng / ml).
- LPS 10, 100 or 1000 ng / ml.
- mouse bone marrow macrophages were first treated with Form II in concentrations of 2, 20 or 200 ⁇ g / mL and stimulated 1 h after treatment with 100 ng / mL or 10 ng / mL LPS. The supernatants were collected 24 h later and the concentrations of TNF-alpha and IL-6 were measured.
- Non-stimulated macrophages non-stimulated macrophages treated with 200 ⁇ g / mL form II and LPS-stimulated macrophages (10 or 100 ng / mL LPS) were used as controls.
- the measured values can be found in Table 8.
- TNF-alpha concentration could be measured in the group with 100 ng / mL LPS-stimulated macrophages in all drug concentrations.
- a significant reduction in TNF-alpha was found in the highest active substance concentration (200 ⁇ g / mL).
- Macrophages in drug concentration at 20 ⁇ g / mL are consistent with IL-6 from an earlier in vitro pilot plant with macrophages, which used a different LPS and drug combination (1 g / mL LPS at 100 ⁇ g / mL) and also had an immunosuppressive effect Form II on stimulated murine macrophages showed. An immunostimulating effect on non-LPS-induced macrophages could not be demonstrated.
- the individual treatment groups were each composed of 5 animals, with two replicates being carried out for the uninfected controls and four for the infected controls and those Form II groups, so that a total of 180 animals were in the experiment. It is known that the toxicity of substances in animal experiments in adolescent mice or rats can affect weight development.
- the weight gain (g) of the uninfected control animals over a period of two days is summarized in Table 9. Table 9
- mice receiving form I of the 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt tended to show lower weight losses in the first 24 hours after infection than the animals in the control groups. This advantage is particularly clear at doses of 20 and 200 ⁇ g of Form I. This indirect indication of a tendency for higher survival in the substance groups is no longer recognizable in the animals that survived the second day.
- Form I and Form II both increased the proportion of surviving animals compared to controls. Thus, both Form I and Form II have a positive influence on the septic process, regardless of their specific action.
- CFU Bacterial load in blood and liver
- Germ number reduction in the blood compared to the controls The inventors regard this as an indication of a better controllability of the infection by the administration of 5-amino-2,3-dihydrophthalazin-l, 4-dione sodium salt, in particular form 2. It should be mentioned restrictively that animals killed before the end of the experiment do not have any germ count determinations , The inventors assume that in a germ count determination at an earlier point in time, the germ burden of the animals that died later would have been particularly high, and thereby the effects caused by forms I and II would become even more pronounced.
- mice Application to specific cytokines, especially IL-6 and TNF-alpha, in mice.
- the blood was collected after 48 hours at the end of the second day of use.
- IL-6 could not be detected in either the substance groups or the control groups.
- TNF-alpha The results for TNF-alpha are summarized in Table 13.
- Form II and controls caused no or no significant increase in TNF-alpha, there was a marked increase after Form I administration compared to the other groups. This effect was most evident in the 20 ⁇ g dose, this group differed significantly (p ⁇ 0.001) from both the control and the Form II groups. Here occurs a specific immunostimulating effect in Form I, which is not observed in Form II.
- Example 9 Liver enzymes / transaminases in healthy experimental animals
- Example 10 Liver enzymes / transaminases in sepsis model
- Example 3 In the sepsis model described in Example 3, it was also investigated what effect the administration of Form I and Form II-specific liver enzymes, in particular the transaminase GOT (AST) and GPT (ALT), in S. pyogenes infected mice.
- AST transaminase GOT
- ALT GPT
- the starting product luminol may also be prepared as follows, it also being possible to produce any desired amounts of luminol, using the equivalents indicated: Production Example Luminol
- the mixture was cooled to room temperature (25 ° C ⁇ 5 ° C) by feeding ice water and stirred overnight.
- the precipitate was filtered and washed with water (3 x 300 mL).
- the moist product was dried on a rotary evaporator at 90 ° C / 20 ⁇ 10 mbar to constant mass.
- 3-nitrophthalhydrazide is converted to 5-amino-2,3-dihydrophthalazine-1,4-dione by dissolving 3-nitrophthalhydrazide (100 g, 0.48 mol) 48.3 mmol) in 3 molar sodium hydroxide solution (1700 mL) with heating to approx. 50-60 ° C.
- Sodium dithionite 300 g, 1 .73 mol is added in portions to this solution. The temperature of the reaction mixture rises to about 80 ° C. After complete addition of sodium dithionite, the reaction mixture is heated to reflux for about 4 h.
- Acetic acid 200 mL, 1.73 mol
- the reaction mixture is cooled overnight.
- the resulting precipitate is isolated and washed with water (3x170 mL).
- the product is dried on a rotary evaporator at about 80 ° C / 20 ⁇ 10 mbar.
- the invention relates to a method for producing the Anhydratform I by mixing 5-amino-2,3-dihydrophthalazine-l, 4-dione (luminol) in sodium hydroxide solution and dropping this solution into a low molecular weight liquid alcohol, preferably ethanol, the solubility product the resulting Luminol sodium salt so lowers that the latter begins to precipitate.
- a low molecular weight liquid alcohol preferably ethanol
- the alcohols should have a degree of purity of preferably> 95%, particularly preferably> 98%.
- the precipitate formed by precipitation is dried according to the invention at temperatures between 50 and at most 90 ° C.
- the crystalline form I can be precipitated by mixing 500-750 ml of a 0.8-1.2 molar luminol suspension with from 500-750 ml of a 1.0-1.3 molar sodium hydroxide solution the mixture is added dropwise at 20-50 ° C. with stirring to 10-15 l of a low molecular weight alcohol, preferably ethanol, preferably with a purity of> 95%, particularly preferably> 98%, and the suspension is subsequently stirred for 15-25 h at 10. 40 ° C is stirred.
- the resulting precipitate is preferably dried in the air after isolation.
- the precipitate is dissolved in a 10-20 fold amount of low molecular weight alcohol, preferably ethanol having a purity of> 95%, particularly preferably> 98%, and the suspension is stirred for 15-25 h at 10 ° C. Stirred at 40 ° C and filtered off.
- the filter cake is then air-dried, at 50 ° C-90 ° C, preferably 50 ° C, after-dried, pulverized and until a water of crystallization of ⁇ 0.4%, preferably ⁇ 0.3%, most preferably ⁇ 0.2% , dried.
- crystalline form I can be prepared as follows:
- crystalline form I can be prepared as follows:
- Schleicher & Schuell Type 1575 Schleicher & Schuell Type 1575
- ethanol preferably with a purity of> 99%
- Suspend the substance with stirring. Stir the suspension for 20 h ⁇ 1 h at 25 ° C ⁇ 5 ° C.
- the water of crystallization should be ⁇ 0.4%, detectable e.g. with Karl Fischer titration. If the water of crystallization is> 0.4%, repeat steps under f) - g).
- crystalline Form I can be prepared by preparing a sodium hydroxide solution in which luminol is introduced. The luminol is dissolved by stirring. Ethanol is then added within 10-40 minutes, whereby the luminol precipitates as a salt.
- crystalline Form I is prepared using the following equivalents of reactants: A solution of 1.0-1.4 equivalents of sodium hydroxide in 4-7 vol / m water is prepared into which 1 equivalent of luminol is added. The reaction mixture is allowed to completely dissolve touched. Subsequently, ethanol (50-70 vol / m) is added dropwise at room temperature (25 ° C ⁇ 5 ° C) within about 10-40 min. The luminol sodium salt falls as
- reaction mixture is stirred for several hours at room temperature (25 ° C ⁇ 5 ° C) and the suspension was filtered; The filter cake is washed with ethanol (about 10-15 vol / m) and optionally dried in a vacuum oven or on a rotary evaporator.
- the crystalline Form I is prepared using the following equivalents of reactants:
- reaction mixture for a maximum of 20 h, preferably for 2 -8 h, more preferably stirred for 8 h at room temperature (25 ° C ⁇ 5 ° C) and the suspension was filtered;
- the filter cake is washed with ethanol (about 13 vol / m) and optionally in a vacuum oven at 50-90 ° C / 1-3 mbar preferably 50-70 ° C, more preferably 50 ° C, or on a rotary evaporator at 20 ⁇ 10 mbar and 50 ° C-90 ° C, preferably 50 ° -70 ° C, particularly preferably 50 ° C, dried.
- Production Example III Form I - scalable batch sizes
- the inventors have found a process for producing crystalline Form II in which luminol is mixed with a sodium hydroxide solution under aqueous conditions and, by adding 2-propanol, the solubility product of the luminol sodium salt is reduced so that the latter begins to precipitate.
- the precipitated luminol sodium salt is washed with 2-propanol and dried to constant mass.
- crystalline Form II is prepared using the following equivalents of reactants.
- a solution of 1.0-2.0 equivalents of sodium hydroxide, preferably 1.1- 1.4 equivalents of sodium hydroxide, more preferably 1.2 equivalents of sodium hydroxide, in 6-7.5 vol / m water is prepared in which 0.5-1 equivalents of luminol is added.
- the reaction mixture is stirred until complete.
- 2-propanol 60-120 vol / m
- the luminol sodium salt precipitates as precipitate.
- the luminol sodium salt precipitates as precipitate.
- 2-propanol 60 vol / m
- room temperature 25 ° C ⁇ 5 ° C
- the suspension is stirred at room temperature for 1-5 h, preferably 2 h, particularly preferably 3 h.
- the product is filtered, washed with 2-propanol (about 15 vol / m), and optionally dried in a vacuum oven at 85 ° C-120 ° C / 1-3 mbar, preferably 90 ° C / l-3 mbar or on a rotary evaporator at 85 ° C - 120 ° C / 20 ⁇ 10 mbar, preferably 90 ° C7 20 ⁇ 10 mbar to constant mass.
- the inventors further show a process which is suitable for batch sizes of luminol of at least 300 g, preferably 400 g, more preferably> 500 g, and is shown by way of example for a batch size of 785 g: Substance Equivalent Approach Amount [mol]
- a solution of 212 g (5.32 mol, 1.2 eq.) Of sodium hydroxide in 4,700 mL of water is prepared. (80 1 reactor).
- the luminol (785 g, 4.43 mol) is added to the sodium hydroxide solution and stirred until it dissolves.
- the result is a clear, brown solution in which 2-propanol (60 vol / m) over a period of 20-30 minutes, preferably 30 min, is pumped.
- the luminol sodium salt precipitates as precipitate.
- the mixture for at least 10 h, preferably 12 h, stirred at room temperature (25 ° C ⁇ 5 ° C).
- the mixture is filtered, the filter cake washed with 2-propanol (13 vol / m) and optionally in a vacuum oven at 85 ° C-120 ° C / 1-3 mbar, preferably 90 ° C / l -3 mbar or on a rotary evaporator at 85 ° C-120 ° C / 20 ⁇ 10 mbar, preferably 90 ° C / 20 ⁇ 10 mbar dried to constant mass.
- crystalline Form II can be prepared by recrystallization from crystalline Form I using the following equivalents:
- the mixture is filtered and the filter cake washed with 2-propanol (about 20 vol / m) and optionally in a vacuum oven at 85 ° C-120 ° C / l -3mbar, preferably 90 ° C / 1 - 3mbar, or on a rotary evaporator dried at 85 ° C-120 ° C / 20 mbar ⁇ 10 mbar to constant mass.
- Crystalline Form I (1 g) is suspended in aqueous 2-propanol (10-20% water) and stirred for at least 10 h, preferably 10-14 h, particularly preferably 10-12 h
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2791327A CA2791327C (en) | 2010-03-01 | 2011-03-01 | Crystalline forms of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same, method for production of said forms and use of said forms for modulating the immune system |
CN201180011760.7A CN102971300B (zh) | 2010-03-01 | 2011-03-01 | 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型、含有它们的药物制剂以及所述晶型的生产方法 |
CH01123/12A CH704794B1 (de) | 2010-03-01 | 2011-03-01 | Kristalline Form zu 5-Amino-2,3-dihydrophthalazin-1,4-dion Natriumsalz, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung. |
NZ601689A NZ601689A (en) | 2010-03-01 | 2011-03-01 | Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
PL11710423T PL2542535T3 (pl) | 2010-03-01 | 2011-03-01 | Formy krystaliczne soli sodowej 5-amino-2,3-dihydroftalazyno-1,4-dionu, kompozycje farmaceutyczne je zawierające i sposoby ich wytwarzania |
DK11710423.2T DK2542535T3 (da) | 2010-03-01 | 2011-03-01 | Krystalformer af 5-amino-2,3-dihydrophthalazin-1,4-dion-natriumsalt, farmaceutiske præparater indeholdende disse samt fremgangsmåder til deres fremstilling |
US13/582,522 US8772294B2 (en) | 2010-03-01 | 2011-03-01 | Crystalline forms for 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
KR1020127025234A KR101770011B1 (ko) | 2010-03-01 | 2011-03-01 | 5-아미노-2,3-디히드로프탈라진-1,4-디온 나트륨염에 대한 결정 형태, 이를 함유하는 약제학적 제제 및 상기 형태를 제조하기 위한 방법 |
JP2012555335A JP6061081B2 (ja) | 2010-03-01 | 2011-03-01 | 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンナトリウム塩の結晶形iまたはii、それを含有する医薬品調製物、5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンナトリウム塩の結晶形iの製造方法、および5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンナトリウム塩の結晶形iiの製造方法 |
EP11710423.2A EP2542535B1 (de) | 2010-03-01 | 2011-03-01 | Kristalline formen von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
AU2011223226A AU2011223226B2 (en) | 2010-03-01 | 2011-03-01 | Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
RSP20140416 RS53492B1 (en) | 2010-03-01 | 2011-03-01 | 5-AMINO-2,3-DIHYDROPHTALAZINE-1,4-DION CRYSTAL FORMS FOR SODIUM CHLORIDE, THEIR PHARMACEUTICAL APPLICATION AND THE PROCEDURE FOR THEIR PRODUCTION |
ES11710423.2T ES2487221T3 (es) | 2010-03-01 | 2011-03-01 | Formas cristalinas de 5-amino-2,3-dihidroftalazina-1,4-diona sal sódica (sal sódica 5-amino-2,3-dihidroftalazina-1,4-diona), preparados farmacéuticos que la contienen y método de producción |
SI201130233T SI2542535T1 (sl) | 2010-03-01 | 2011-03-01 | Kristalinične oblike natrijeve soli 5-amino-2,3-dihidroftalazin-1,4-diona, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravo |
BR112012021857-3A BR112012021857B1 (pt) | 2010-03-01 | 2011-03-01 | Formas cristalinas para sal de sódio de 5-amino-2,3-di-hidro ftalazino-1,4-diona, seus processos de produção, e preparações farmacêuticas |
RU2012141274/04A RU2585677C2 (ru) | 2010-03-01 | 2011-03-01 | Кристаллические формы натриевой соли 5-амино-2,3-дигидрофталазин-1,4-диона, содержащие их фармацевтические препараты и способы получения указанных форм |
ZA2012/06264A ZA201206264B (en) | 2010-03-01 | 2012-08-20 | Crystalline forms for 5-amino-2,3-dihydrophathalazine-1,4-dione sodium salt,pharmaceutical preparations containing the same and method for the production of said forms |
IL221680A IL221680A (en) | 2010-03-01 | 2012-08-29 | Crystalline Forms for Sodium Salt of 5-Amino-3,2-Dihydropathalazine-4,1-Deon |
US14/247,626 US9079863B2 (en) | 2010-03-01 | 2014-04-08 | Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
HRP20140752AT HRP20140752T1 (hr) | 2010-03-01 | 2014-08-06 | Kristalni oblici 5-amino-2,3-dihidroftalazin-1,4-dion natrijeve soli, farmaceutski pripravci koji ih sadrže i postupak za njihovu proizvodnju |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10002067 | 2010-03-01 | ||
EP10002067.6 | 2010-03-01 | ||
EP10075744 | 2010-11-25 | ||
EP10075744.2 | 2010-11-25 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/582,522 A-371-Of-International US8772294B2 (en) | 2010-03-01 | 2011-03-01 | Crystalline forms for 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
US201213582522A A-371-Of-International | 2010-03-01 | 2012-09-04 | |
US14/247,626 Division US9079863B2 (en) | 2010-03-01 | 2014-04-08 | Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011107295A1 true WO2011107295A1 (de) | 2011-09-09 |
Family
ID=43828190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/001124 WO2011107295A1 (de) | 2010-03-01 | 2011-03-01 | Kristalline formen zu 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
Country Status (23)
Country | Link |
---|---|
US (2) | US8772294B2 (de) |
EP (2) | EP2774920A1 (de) |
JP (2) | JP6061081B2 (de) |
KR (1) | KR101770011B1 (de) |
CN (3) | CN105859634B (de) |
AU (1) | AU2011223226B2 (de) |
BR (1) | BR112012021857B1 (de) |
CA (1) | CA2791327C (de) |
CH (1) | CH704794B1 (de) |
CY (1) | CY1115585T1 (de) |
DK (1) | DK2542535T3 (de) |
ES (1) | ES2487221T3 (de) |
HK (2) | HK1223929A1 (de) |
HR (1) | HRP20140752T1 (de) |
IL (1) | IL221680A (de) |
NZ (1) | NZ601689A (de) |
PL (1) | PL2542535T3 (de) |
PT (1) | PT2542535E (de) |
RS (1) | RS53492B1 (de) |
RU (1) | RU2585677C2 (de) |
SI (1) | SI2542535T1 (de) |
WO (1) | WO2011107295A1 (de) |
ZA (1) | ZA201206264B (de) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8772294B2 (en) | 2010-03-01 | 2014-07-08 | Metriopharm Ag | Crystalline forms for 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
WO2016096143A1 (de) | 2014-12-18 | 2016-06-23 | Metriopharm Ag | Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
WO2017140430A1 (en) | 2016-02-16 | 2017-08-24 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
EP3248602A1 (de) | 2016-05-26 | 2017-11-29 | MetrioPharm AG | Verwendung von 5-amino-2,3-dihydro-1,4-phthalazindion bei der behandlung von entzündlichen und/oder degenerativen erkrankungen der sehnen, gelenkbänder, gelenkkapseln und schleimbeutel |
WO2018082814A1 (en) | 2016-11-07 | 2018-05-11 | Metriopharm Ag | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis |
RU2673452C1 (ru) * | 2017-08-15 | 2018-11-27 | Межрегиональное общественное учреждение "Институт инженерной физики" | Способ получения активной фармацевтической субстанции, представляющей собой аминодигидрофталазиндион натрия |
EP3511325A1 (de) | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Verfahren zur solubilisierung von 5-amino-2,3-dihydro-1,4-phthalazinedion |
EP3858358A1 (de) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Verwendung von 5-amino-2,3-dihydro-1,4-phthalazindion zur behandlung von seltenen chronischen entzündlichen lungenerkrankungen |
EP3858328A1 (de) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Verwendung von 5-amino-2,3-dihydro-1,4-phthalazindion zur inhalativen behandlung von entzündlichen lungenerkrankungen |
WO2021190783A1 (en) | 2020-03-25 | 2021-09-30 | Metriopharm Ag | 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury |
WO2021249667A1 (en) | 2020-06-10 | 2021-12-16 | Metriopharm Ag | Compound for the treatment of coronaviral infections |
WO2022008093A1 (en) | 2020-07-09 | 2022-01-13 | Metriopharm Ag | Glucocorticoid-sparing agent |
EP3981405A1 (de) | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Verbindung zur behandlung von coronavirusinfektionen |
WO2022117221A1 (en) | 2020-12-02 | 2022-06-09 | Metriopharm Ag | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
EP4193994A1 (de) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Kombination von 5-amino-2,3-dihydro-1,4-phtalazinedion und einem 6'-methoxycinchonan-9-ol zur verwendung bei der behandlung von coronaviralen infektionen |
EP4209219A1 (de) | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Kombination von budesonid und 5-amino-2,3-dihydro-1,4-phtalazindion |
EP4248963A1 (de) | 2022-03-25 | 2023-09-27 | MetrioPharm AG | Kombination von 5-amino-2,3-dihydro-1,4-phtalazindion und einem fumarsäureester |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2796476T3 (es) * | 2016-02-16 | 2020-11-27 | Metriopharm Ag | Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona |
RU2625267C1 (ru) * | 2016-09-22 | 2017-07-12 | Общество с ограниченной ответственностью "АБИДАФАРМА" | Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты |
CN106810501B (zh) * | 2017-01-23 | 2019-09-10 | 湖北新德晟材料科技有限公司 | 一种利用一锅法合成鲁米诺或异鲁米诺的方法 |
RU2635769C1 (ru) * | 2017-02-08 | 2017-11-15 | Адмир Мусаевич Абидов | Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения |
EP3870175A1 (de) * | 2018-10-26 | 2021-09-01 | Immunopharma Plus D.o.o | Orale aminodihydrophthalazinedionzusammensetzungen und deren verwendung zur behandlung von nichtviraler hepatitis |
RU2756568C1 (ru) * | 2021-03-24 | 2021-10-01 | Акционерное общество "Щелково Агрохим" | Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0617024A1 (de) | 1993-02-19 | 1994-09-28 | L.I.M.A.D. Limited | Pharmakologische Verwendung von Phthaloylhydrazid-Derivaten; ihre Zusammensetzung und Anwendung |
US5512573A (en) | 1993-02-19 | 1996-04-30 | L.I.M.A.D. Limited | Use of phthaloylhydrazide derivatives as anti-hypoxic and defensive agents |
RU2113222C1 (ru) | 1997-09-30 | 1998-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Иммуномодулирующее средство |
EP1203587A1 (de) | 2000-03-28 | 2002-05-08 | Abidov, Musea Tazhudinovich | Arzneimittel und dessen herstellungsprozess |
RU2211036C2 (ru) | 2001-11-20 | 2003-08-27 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) и способ его производства |
US20030195183A1 (en) | 2000-08-02 | 2003-10-16 | Zhilov Valerii Khazhumuratovich | Method for correcting immune system of live body |
US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
WO2010082858A2 (en) * | 2009-01-16 | 2010-07-22 | Abidopharma Pl Sp. Z.O.O | New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089086C (zh) * | 1988-03-31 | 2002-08-14 | 兰德尔·L·米尔斯 | 鲁米纳得类药物 |
RU2138264C1 (ru) | 1999-05-06 | 1999-09-27 | Абидов Муса Тажудинович | Способ получения лекарственного препарата галавит |
RU2169139C1 (ru) | 2000-08-02 | 2001-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона |
RU2222327C2 (ru) | 2002-03-22 | 2004-01-27 | Общество с ограниченной ответственностью "Абидофарма" | Способ получения лекарственного препарата |
RU2238730C1 (ru) | 2003-02-17 | 2004-10-27 | Абидов Муса Тажудинович | Лекарственный препарат |
RU2302863C2 (ru) | 2003-04-18 | 2007-07-20 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) |
CN1217193C (zh) * | 2003-07-30 | 2005-08-31 | 中国药科大学 | 心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法 |
US8592421B2 (en) | 2003-08-04 | 2013-11-26 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
EP2393361B1 (de) | 2009-02-06 | 2016-12-07 | Bach Pharma, Inc. | Pharmazeutisch reine phthalazindione, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen |
SI2542535T1 (sl) | 2010-03-01 | 2014-09-30 | Metripharm Ag | Kristalinične oblike natrijeve soli 5-amino-2,3-dihidroftalazin-1,4-diona, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravo |
-
2011
- 2011-03-01 SI SI201130233T patent/SI2542535T1/sl unknown
- 2011-03-01 PT PT117104232T patent/PT2542535E/pt unknown
- 2011-03-01 CN CN201610087179.8A patent/CN105859634B/zh active Active
- 2011-03-01 CH CH01123/12A patent/CH704794B1/de not_active IP Right Cessation
- 2011-03-01 WO PCT/EP2011/001124 patent/WO2011107295A1/de active Application Filing
- 2011-03-01 BR BR112012021857-3A patent/BR112012021857B1/pt active IP Right Grant
- 2011-03-01 DK DK11710423.2T patent/DK2542535T3/da active
- 2011-03-01 RS RSP20140416 patent/RS53492B1/en unknown
- 2011-03-01 CN CN201180011760.7A patent/CN102971300B/zh active Active
- 2011-03-01 NZ NZ601689A patent/NZ601689A/en unknown
- 2011-03-01 EP EP14001134.7A patent/EP2774920A1/de not_active Withdrawn
- 2011-03-01 AU AU2011223226A patent/AU2011223226B2/en active Active
- 2011-03-01 ES ES11710423.2T patent/ES2487221T3/es active Active
- 2011-03-01 CN CN201610087203.8A patent/CN105726541A/zh active Pending
- 2011-03-01 PL PL11710423T patent/PL2542535T3/pl unknown
- 2011-03-01 EP EP11710423.2A patent/EP2542535B1/de active Active
- 2011-03-01 US US13/582,522 patent/US8772294B2/en active Active
- 2011-03-01 JP JP2012555335A patent/JP6061081B2/ja active Active
- 2011-03-01 CA CA2791327A patent/CA2791327C/en active Active
- 2011-03-01 KR KR1020127025234A patent/KR101770011B1/ko active IP Right Grant
- 2011-03-01 RU RU2012141274/04A patent/RU2585677C2/ru active
-
2012
- 2012-08-20 ZA ZA2012/06264A patent/ZA201206264B/en unknown
- 2012-08-29 IL IL221680A patent/IL221680A/en active IP Right Grant
-
2014
- 2014-04-08 US US14/247,626 patent/US9079863B2/en active Active
- 2014-08-04 CY CY20141100589T patent/CY1115585T1/el unknown
- 2014-08-06 HR HRP20140752AT patent/HRP20140752T1/hr unknown
-
2016
- 2016-06-09 JP JP2016115125A patent/JP6206689B2/ja active Active
- 2016-10-24 HK HK16112165.6A patent/HK1223929A1/zh unknown
- 2016-10-24 HK HK16112162.9A patent/HK1223836A1/zh unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0617024A1 (de) | 1993-02-19 | 1994-09-28 | L.I.M.A.D. Limited | Pharmakologische Verwendung von Phthaloylhydrazid-Derivaten; ihre Zusammensetzung und Anwendung |
US5512573A (en) | 1993-02-19 | 1996-04-30 | L.I.M.A.D. Limited | Use of phthaloylhydrazide derivatives as anti-hypoxic and defensive agents |
US5543410A (en) | 1993-02-19 | 1996-08-06 | L.I.M.A.D. Limited | Pharmacological use of phthaloylhydrazide derivatives; combination and application thereof |
RU2113222C1 (ru) | 1997-09-30 | 1998-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Иммуномодулирующее средство |
EP1203587A1 (de) | 2000-03-28 | 2002-05-08 | Abidov, Musea Tazhudinovich | Arzneimittel und dessen herstellungsprozess |
US6489326B1 (en) | 2000-03-28 | 2002-12-03 | Anatoliy Ivanovich Pavlov | Medicinal preparation and process for manufacturing thereof |
US20030195183A1 (en) | 2000-08-02 | 2003-10-16 | Zhilov Valerii Khazhumuratovich | Method for correcting immune system of live body |
RU2211036C2 (ru) | 2001-11-20 | 2003-08-27 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) и способ его производства |
US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
WO2010082858A2 (en) * | 2009-01-16 | 2010-07-22 | Abidopharma Pl Sp. Z.O.O | New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine |
Non-Patent Citations (11)
Title |
---|
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: DOI:10.1007/3-540-69178-2_5 * |
DESCOTES, EXPERT OPIN. DRUG METAB. TOXICOL., vol. 4, no. 12, 2008, pages 1537 - 1549 |
DIEL ET AL., Z RHEUMATOL, vol. 5, 2009, pages 411 - 416 |
GRIESSER: "Polymorphisms in the Pharmaceutical Industry", 2006, pages: 211 - 234 |
GUNDERMANN KARL D ET AL: "Konstitution und chemilumineszenz, IV Chemilumineszenz von Diazachinonen zum Mechanismus der Chemilumineszenz cyclischer Diacylhydrazide", JUSTUS LIEBIGS ANNALEN DER CHEMIE, VERLAG CHEMIE GMBH, WEINHEIM; DE, vol. 738, 1 January 1970 (1970-01-01), pages 140 - 160, XP008135435, ISSN: 0075-4617 * |
HALEBLIAN; MCCRONE, JOURNAL OFPHARMACEUTICAL SCIENCES, vol. 58, 1969, pages 911 - 929 |
HOFFMANN, INTENSIVMED, vol. 42, 2005, pages 371 - 377 |
MILLER ET AL.: "Polymorphisms in the Pharmaceutical Industry", 2006, pages: 385 - 403 |
SUNTHARALINGAM ET AL., N ENGL J MED, vol. 355, 2006, pages 1018 - 28 |
ULRICH; JONES, NACHRICHTEN AUS DER CHEMIE, vol. 53, 2005, pages 19 - 23 |
WILLIAMSON, K. L.: "Macroscale and Microscale Organic Experiments", 1994, D.C. HEATH: LEXINGTON |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8772294B2 (en) | 2010-03-01 | 2014-07-08 | Metriopharm Ag | Crystalline forms for 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
US9079863B2 (en) | 2010-03-01 | 2015-07-14 | Metriopharm Ag | Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
WO2016096143A1 (de) | 2014-12-18 | 2016-06-23 | Metriopharm Ag | Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
US10258620B2 (en) | 2014-12-18 | 2019-04-16 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form |
WO2017140430A1 (en) | 2016-02-16 | 2017-08-24 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
US11111218B2 (en) | 2016-02-16 | 2021-09-07 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
EP3248602A1 (de) | 2016-05-26 | 2017-11-29 | MetrioPharm AG | Verwendung von 5-amino-2,3-dihydro-1,4-phthalazindion bei der behandlung von entzündlichen und/oder degenerativen erkrankungen der sehnen, gelenkbänder, gelenkkapseln und schleimbeutel |
WO2017202496A1 (en) | 2016-05-26 | 2017-11-30 | Metriopharm Ag | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the ligaments of the joints, articular capsules and bursae |
WO2018082814A1 (en) | 2016-11-07 | 2018-05-11 | Metriopharm Ag | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis |
RU2673452C1 (ru) * | 2017-08-15 | 2018-11-27 | Межрегиональное общественное учреждение "Институт инженерной физики" | Способ получения активной фармацевтической субстанции, представляющей собой аминодигидрофталазиндион натрия |
EP3511325A1 (de) | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Verfahren zur solubilisierung von 5-amino-2,3-dihydro-1,4-phthalazinedion |
WO2019137825A1 (en) | 2018-01-11 | 2019-07-18 | Metriopharm Ag | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
EP3858328A1 (de) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Verwendung von 5-amino-2,3-dihydro-1,4-phthalazindion zur inhalativen behandlung von entzündlichen lungenerkrankungen |
WO2021151619A1 (en) | 2020-01-31 | 2021-08-05 | Metriopharm Ag | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
WO2021151620A1 (en) | 2020-01-31 | 2021-08-05 | Metriopharm Ag | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases |
EP3858358A1 (de) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Verwendung von 5-amino-2,3-dihydro-1,4-phthalazindion zur behandlung von seltenen chronischen entzündlichen lungenerkrankungen |
WO2021190783A1 (en) | 2020-03-25 | 2021-09-30 | Metriopharm Ag | 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury |
WO2021249667A1 (en) | 2020-06-10 | 2021-12-16 | Metriopharm Ag | Compound for the treatment of coronaviral infections |
WO2022008093A1 (en) | 2020-07-09 | 2022-01-13 | Metriopharm Ag | Glucocorticoid-sparing agent |
EP3981405A1 (de) | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Verbindung zur behandlung von coronavirusinfektionen |
WO2022117221A1 (en) | 2020-12-02 | 2022-06-09 | Metriopharm Ag | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
EP4193994A1 (de) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Kombination von 5-amino-2,3-dihydro-1,4-phtalazinedion und einem 6'-methoxycinchonan-9-ol zur verwendung bei der behandlung von coronaviralen infektionen |
WO2023104327A1 (en) | 2021-12-08 | 2023-06-15 | Metriopharm Ag | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections |
EP4209219A1 (de) | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Kombination von budesonid und 5-amino-2,3-dihydro-1,4-phtalazindion |
WO2023131578A1 (en) | 2022-01-07 | 2023-07-13 | Metriopharm Ag | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phthalazinedione |
EP4248963A1 (de) | 2022-03-25 | 2023-09-27 | MetrioPharm AG | Kombination von 5-amino-2,3-dihydro-1,4-phtalazindion und einem fumarsäureester |
WO2023179905A1 (en) | 2022-03-25 | 2023-09-28 | Metriopharm Ag | Combination of 5-amino-2,3-dihydro-1,4-phthalazinedione and a fumaric acid ester |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2542535B1 (de) | Kristalline formen von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung | |
DE69635106T2 (de) | Guaninderivat | |
EP0212537B1 (de) | Verfahren zur Herstellung einer stabilen Modifikation von Torasemid sowie Arzneimittel enthaltend Torasemid | |
EP4328218A2 (de) | Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat | |
DD267490A5 (de) | Verfahren zur herstellung von wasserfreiem, kristallinem natriumsalz von 5-chlor-3-(2-thenoyl)-2-odindol-1-carboxamid | |
DE29924789U1 (de) | Neue Kristallmodifikation N von Torasemid | |
DD202573A5 (de) | Verfahren zur herstellung von 1-aethyl-6-fluor-1,4dihydro-4-oxo-7-(1-piperazinyl)-1,8 naphthyridin-3-carbonsaeure | |
DD208613A5 (de) | Verfahren zur herstellung neuer kristallmodifikationen des (+)-catechinmonohydrats und des (+)-catechinanhydrats | |
DE602004007505T2 (de) | Pioglitazonsulfat, pharmazeutische zusammensetzungen und deren anwendung | |
AT390616B (de) | Verfahren zur herstellung von neuem, kristallinem cephalexinhydrochloridmonohydrat und dessen verwendung zur herstellung eines arzneimittels | |
DD218349A5 (de) | Verfahren zur herstellung von 2-tert.-butylamino-3-chlorpropiophenonmaleat | |
EP0046506B1 (de) | Vincamin-saccharinat und dieses enthaltende Arzneimittel | |
DE60222643T2 (de) | Kristallines isoxazol-derivat und medizinisches präparat daraus | |
DE3424997C2 (de) | ||
DE2329452A1 (de) | Antibakterielle mittel und verfahren zu deren herstellung | |
DD242405A5 (de) | Verfahren zur herstellung einer neuen kristallinen form eines benzothlazindioxid-salzes | |
DE2655130C3 (de) | Eine praktisch lösungsmittelfreie Kristallform des Cefacetril-Natriumsalzes | |
EP1362030B1 (de) | Neues benzoylguanidinsalz | |
DE2704935A1 (de) | Neues piperazinyluracilsalz | |
EP0253293B1 (de) | Neue Guanidiniumasparaginate | |
EP4093374B1 (de) | Komplex aus 7-deacetylforskolin und pvp | |
DE1792270C3 (de) | Antirheumatikum enthaltend ein Magnesium- oder Calciumsalz eines Malonsäurehydrazid s | |
DE2545602A1 (de) | Neue nitrofurylverbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
CH337857A (de) | Verfahren zur Herstellung einer hochwirksamen antibakteriellen Verbindung | |
DE2921656A1 (de) | (1-alkyl-5-nitro-2-imidazolyl)vinyl- glyoxal-diacetale, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische mittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180011760.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11710423 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10201200001123 Country of ref document: CH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011710423 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012555335 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2791327 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 221680 Country of ref document: IL Ref document number: 7527/DELNP/2012 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13582522 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20127025234 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012141274 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2011223226 Country of ref document: AU Date of ref document: 20110301 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012021857 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2014/0416 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: 112012021857 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120830 |